BioNTech SE(BNTX) - 2023 Q1 - Quarterly Report

The increase of intangible assets by €158.9 million during the three months ended March 31, 2023 is mainly due to licenses acquired that meet the definition of identifiable assets in the amount of €158.0 million in connection with the License and Collaboration Agreements entered into between us and Duality Biologics (Suzhou) Co. Ltd., Shanghai, China, in March 2023. Set out below is an overview of financial assets, other than cash and cash equivalents, held as of March 31, 2023 and December Derivatives not ...